Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in INSM — INSMED Inc

CIK 1423053 MIAMI, FL
Back to INSM Full portfolio

Position in INSM

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$356,894,009
+$155,478,388 QoQ
Shares Held
2,182,571
+88.6% QoQ
Ownership
1.01%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in INSM Over Time

Shares Held

Position Value (USD)

Derivatives in INSM

reported options exposure · as of Mar 31, 2026
CallValue
$62,088,544
CallShares
379,700
PutValue
$8,306,816
PutShares
50,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,780,537,601 across 374 Biotechnology names. INSM ranks #1 (6.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
This page 		2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in INSM

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $62,088,544 379,700
2026-03-31 $8,306,816 50,800
2026-03-31 $356,894,009 2,182,571
2025-12-31 $38,079,952 218,800
2025-12-31 $75,341,916 432,900
2025-12-31 $201,415,621 1,157,295
2025-09-30 $28,067,549 194,900
2025-09-30 $296,320,880 2,057,641
2025-09-30 $49,035,405 340,500
2025-06-30 $10,959,696 108,900
2025-06-30 $9,641,312 95,800
2025-06-30 $154,308,996 1,533,277
2025-03-31 $5,149,575 67,500
2025-03-31 $5,996,394 78,600
2025-03-31 $28,594,636 374,815
2024-12-31 $13,462,800 195,000
2024-12-31 $10,390,520 150,500
2024-12-31 $22,350,664 323,735
2024-09-30 $20,388,900 279,300
2024-09-30 $24,569,026 336,562
2024-09-30 $5,956,800 81,600
2024-06-30 $53,582,982 799,746
2024-06-30 $21,158,600 315,800
2024-06-30 $12,214,100 182,300
2024-03-31 $3,480,779 128,300
2024-03-31 $25,164,783 927,563
2024-03-31 $2,086,297 76,900
2023-12-31 $387,375 12,500
2023-12-31 $32,422,171 1,046,214
2023-12-31 $2,017,449 65,100
2023-09-30 $2,275,025 90,100
2023-09-30 $1,934,150 76,600
2023-09-30 $14,629,395 579,382
2023-06-30 $453,650 21,500
2023-06-30 $1,067,660 50,600
2023-06-30 $8,024,160 380,292
2023-03-31 $175,615 10,300
2023-03-31 $17,258,044 1,012,202
2023-03-31 $1,011,065 59,300
2022-12-31 $795,204 39,800
2022-12-31 $317,682 15,900
2022-12-31 $10,501,347 525,593
2022-09-30 $7,922,735 367,815
2022-09-30 $299,406 13,900
2022-09-30 $499,728 23,200
2022-06-30 $5,182,416 262,800
2022-06-30 $368,764 18,700
2022-03-31 $559,300 23,800
2022-03-31 $3,625,768 154,288
2021-12-31 $681,000 25,000

Report a Problem

Category
Description
Email (optional, for follow-up)